Acinetobacter Infections among Adult Patients in Qatar: A 2-Year Hospital-Based Study

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 2016, Issue , 2016, Pages

  Al Samawi, Musaed Saad ^a   Khan, Fahmi Yousef ^b   Eldeeb, Yasser ^a   Almaslamani, Muna ^b   Alkhal, Abdullatif ^b   Alsoub, Hussam ^b   Ghadban, Wissam ^a   Howady, Faraj ^b   Hashim, Samar ^b  

^a Al Khor Hospital   (Qatar)

^b HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; COLISTIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; GENERAL HOSPITAL; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; QATAR; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK;

EID: 84982812083     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2016/6873689     Document Type: Article

References (35)

1. M. M. Kock, A. N. Bellomo, N. Storm, and M. M. Ehlers, "Prevalence of carbapenem resistance genes in Acinetobacter baumannii isolated from clinical specimens obtained from an academic hospital in South Africa, " Southern African Journal of Infectious Diseases, vol. 28, pp. 28-32, 2013.
2. M. Wadl, K. Heckenbach, I. Noll et al., "Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four german university hospitals, 2002-2006, " Infection, vol. 38, no. 1, pp. 47-51, 2010.
3. W.-S. Leung, C.-M. Chu, K.-Y. Tsang, F.-H. Lo, K.-F. Lo, and P.-L. Ho, "Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome, " Chest, vol. 129, no. 1, pp. 102-109, 2006.
4. P. E. Fournier and H. Richet, "The epidemiology and control of Acinetobacter baumannii in health care facilities, " Clinical Infectious Diseases, vol. 42, no. 5, pp. 692-699, 2006.
5. F. Y. Khan, M. Abukhattab, and K. Baager, "Nosocomial postneurosurgical acinetobacter baumannii meningitis: a retrospective study of six cases admitted to hamad general hospital, Qatar, " Journal of Hospital Infection, vol. 80, no. 2, pp. 176-179, 2012.
6. F. Y. Khan, S. S. Elshafie, M. Almaslamani et al., "Epidemiology of bacteraemia in Hamad general hospital, Qatar: a one year hospital-based study, " Travel Medicine and Infectious Disease, vol. 8, no. 6, pp. 377-387, 2010.
7. C.-I. Kang, S.-H. Kim, B. P. Wan et al., "Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome, " Antimicrobial Agents and Chemotherapy, vol. 49, no. 2, pp. 760-766, 2005.
8. N. B. A. Ntusi, M. Badri, H. Khalfey et al., "ICU-associated Acinetobacter baumannii colonisation/infection in a highHIVprevalence resource-poor setting, " PLoS ONE, vol. 7, no. 12, Article ID e52452, 2012.
9. R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine, " Chest, vol. 136, no. 5, p. e28, 2009.
10. M. E. Falagas, P. K. Koletsi, and I. A. Bliziotis, "The diversity of definitions of multidrug-resistant (MDR) and pandrugresistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa, " Journal of Medical Microbiology, vol. 55, no. 12, pp. 1619-1629, 2006.
11. Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing; 24th informational supplement, " CLSI M100-S21, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2011.
12. G. Rivera, J. Bulnes, C. Castillo, M. C. Ajenjo, P. García, and J. Labarca, "Extensively drug-resistant Acinetobacter baumannii isolated in a university hospital: role of inter-hospital transmission, " Journal of Infection in Developing Countries, vol. 10, no. 1, pp. 96-99, 2016.
13. L. L. Maragakis and T. M. Perl, "Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options, " Clinical Infectious Diseases, vol. 46, no. 8, pp. 1254-1263, 2008.
14. J. Rodríguez-Baño, J. M. Cisneros, F. Fernández-Cuenca et al., "Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals, " Infection Control and Hospital Epidemiology, vol. 25, no. 10, pp. 819-824, 2004.
15. N. Jaggi, P. Sissodia, and L. Sharma, "Acinetobacter baumannii isolates in a tertiary care hospital: antimicrobial resistance and clinical significance, " Journal of Microbiology and Infectious Diseases, vol. 2, pp. 57-63, 2012.
16. S. Begum, F. Hasan, S. Hussain, and A. A. Shah, "Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from tertiary care hospital in Islamabad, Pakistan, " Pakistan Journal ofMedical Sciences, vol. 29, no. 5, pp. 1253-1258, 2013.
17. M. Chaudhary and A. Payasi, "Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing Acinetobacter baumanii in Indian intensive care units, " Journal of Pharmacy Research, vol. 7, no. 2, pp. 175-180, 2013.
18. N. Sinha, J. Agarwal, S. Srivastava, and M. Singh, "Analysis of carbapenem-resistant Acinetobacter from a tertiary care setting in North India, " Indian Journal of Medical Microbiology, vol. 31, no. 1, pp. 60-63, 2013.
19. G. Mahajan, S. Sheemar, S. Chopra, J. Kaur, D. Chowdhary, and S. K. Makhija, "Carbapenem resistance and phenotypic detection of carbapenemases in clinical isolates of acinetobacter baumannii, " Indian Journal ofMedical Sciences, vol. 65, no. 1, pp. 18-25, 2010.
20. A. Versporten, S. Coenen, N. Adriaenssens et al., "European surveillance of antimicrobial consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009), " Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, Article IDdkr530, pp. 518-518, 2012.
21. D. Gur, V. Korten, S. Unal, L. M. Deshpande, and M. Castanheira, "Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites, " Journal of Medical Microbiology, vol. 57, no. 12, pp. 1529-1532, 2008.
22. H. Ziglam, O. Elahmer, S. Amri et al., "Antimicrobial resistance patterns among Acinetobacter baumannii isolated from burn intensive care unit in Tripoli, Libya, " International Arabic Journal of Antimicrobial Agents, vol. 2, no. 3, 2012.
23. J. Moradi, F. B. Hashemi, and A. Bahador, "Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature, " Osong Public Health and Research Perspectives, vol. 6, no. 2, pp. 79-86, 2015.
24. H. Aydemir, G. Celebi, N. Piskin et al., "Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital, " Japanese Journal of Infectious Diseases, vol. 65, no. 1, pp. 66-71, 2012.
25. L. Poirel and P. Nordmann, "Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology, " Clinical Microbiology and Infection, vol. 12, no. 9, pp. 826-836, 2006.
26. U. J. Kim, H. K. Kim, J. H. An, S. K. Cho, K. Park, and H. Jang, "Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections, " Chonnam Medical Journal, vol. 50, no. 2, pp. 37-44, 2014.
27. A. Ulu-Kilic, S. Ahmed, E. Alp, and M. Do?ganay, "Challenge of intensive care unit-acquired infections and Acinetobacter baumannii in developing countries, " OA Critical Care, vol. 1, no. 1, 2013.
28. J. W. Liu, L. S. Wang, Y. J. Cheng et al., "In-vitro activity of tigecycline against clinical isolates of Acinetobacterbaumannii in Taiwan, " International Journal ofAntimicrobialAgents, vol. 32, supplement 3, pp. S188-191, 2008.
29. R. Ricciardi, A. M. Ricciardi, and G. Danzi, "In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates, " Infezioni inMedicina, vol. 17, no. 4, pp. 236-239, 2009.
30. S. Tiengrim, C. Tribuddharat, and V. Thamlikitkul, "In vitro activity of tigecycline against clinical isolates of multidrugresistant Acinetobacter baumannii in SirirajHospital, Thailand, " Journal of the Medical Association of Thailand, vol. 89, supplement 5, pp. S102-S105, 2006.
31. D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas, "Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence, " Journal of Antimicrobial Chemotherapy, vol. 62, no. 1, pp. 45-55, 2008.
32. F. E. ö. Akin, A. Bayram, and I. Balci, "Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline inmulti-resistant acinetobacter baumannii isolates, " Mikrobiyoloji Bulteni, vol. 44, no. 2, pp. 203-210, 2010.
33. Y. K. Park, S.-I. Jung, K.-H. Park et al., "Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea, " DiagnosticMicrobiology and InfectiousDisease, vol. 64, no. 1, pp. 43-51, 2009.
34. M. SinirtaŞ, H. Akalin, and S. Gediko?glu, "Investigation of colistin sensitivity via three different methods in Acinetobacter baumannii isolates with multiple antibiotic resistance, " International Journal of Infectious Diseases, vol. 13, no. 5, pp. e217-e220, 2009.
35. R. H. Sunenshine, M.-O. Wright, L. L. Maragakis et al., "Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization, " Emerging Infectious Diseases, vol. 13, no. 1, pp. 97-103, 2007.